
The oncology field moves so quickly that it can be hard to keep track of the latest innovations. Ben Hargreaves …

AstraZeneca’s biologic R&D unit MedImmune is set to enter a partnership with Israeli drug firm Compugen to develop bi-specific and …

As we finally pass into Spring after what still feels like a particularly stubborn Winter, we are pleased to announce …

Celgene has inked a new multi-year partnership with biotech firm Vividion Therapeutics to leverage the latter’s proteomics and chemistry platforms …

MSD, known as Merck in the US, has announced it is to buy Australian viral immuno-oncology firm Viralytics for $394 …

Roche has announced it is to acquire privately held healthcare and technology firm Flatiron Health for $1.9 billion to leverage …

Disulfiram has been known as an anti-drinking compound for nearly seven decades. Initially, the compound was used in the vulcanisation …

Peter Naredi, of ECCO, explores how a multi-dimensional approach is necessary to ensure that patients receive access to the most …

The EMA received a broadside just less than two week ago from a group of researchers that had studied data …

A new study conducted by King’s College London and LSE has found that of 48 treatments approved between 2009 and …

The September edition of Pharmafocus is now available – click here to read online.

It is widely known that Takeda is keen to build its portfolio in oncology and it has made another move …

A proof-of-concept study conducted at the Duke Cancer Institute (DCI) in North Carolina has shown that an investigational antibody has …

Loxo Oncology’s lead therapy larotrectinib made a big impact at the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting, …

The Institute of Cancer Research (ICR) has collaborated with sites across Scotland, Italy and the US to study the disease …